Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:~* Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.~* Must have a baseline EDSS between 0.0 and 5.0, inclusive.~* Must have relapsing-remitting disease course.~Key Exclusion Criteria:~* Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:~* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.~* Pregnant or nursing women.~Note: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received two placebo capsules orally three times daily (TID)
- BG00012 240 mg Twice Daily (BID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
- BG00012 240 mg 3 Times Daily (TID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally three times daily (TID)

Based on this trial design, predict the completion outcome and termination type (if applicable).